Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Nucleoproteins – e.g. – chromatin – chromosomal proteins,...
Patent
1996-08-21
1998-12-08
Walsh, Stephen
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Nucleoproteins, e.g., chromatin, chromosomal proteins,...
435 691, 4353201, 536 234, 536 235, C07K 14435, C07K 1447, C12N 1512, C12N 1563
Patent
active
058470832
ABSTRACT:
A modified p53 protein or peptide having DNA binding in which amino acid residue 284 of a p53 protein or protein fragment is changed to Arginine or Lysine, is described. Also described are nucleotide sequences encoding the modified protein and vectors capable of expressing it.
REFERENCES:
patent: 5362623 (1994-11-01), Vogelstein et al.
patent: 5569824 (1996-10-01), Donehower et al.
patent: 5573925 (1996-11-01), Halazonetis
Brugidou et al. The retro-inverso form of a homeobox-derived short peptide is rapidly internalized by cultured neurons: a new basis for an efficient intracelular delivery system. Biochemical and Biophysical Research Communications. vol. 214, No. 2, pp. 685-693, Sep. 14, 1995.
Mayr et al. Sequence of an exon of the canine p53 gene--mutation in a papilloma. British Verterinary Journal. vol. 150, pp. 81-84, 1994.
T. Halazonetis et al, "Conformational Shifts Propagate from the Oligomerization Domain of p53 to its Tetrameric DNA Binding Domain and Restore DNA Binding to Select p53 Mutants", EMBO J., 12(13):5057-5064
T. Halazonetis et al, "Wild-Type p53 Adopts a `Mutant`-Like Conformation II!.
Y. Wang et al, "p53 Domains: Identification and Characterization of Two Autonomous DNA-Binding Regions", Genes & Development, 7:2575-2586 (Dec.,
P. Wang et al, "p53 Domains: Structure, Oligomerization, and
T. Hupp et al, "Regulation of the Specific DNA Binding Function of p53",
T. Hupp et al, "Activation of the Cryptic DNA Binding Function of Mutant II!.
T. Fujiwara et al, "A Retroviral Wild-type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis",
T. Fujiwara et al, "Induction of Chemosensitivity in Human Lung Cancer Cells in vivo by Adenovirus-Mediated Transfer of the Wild-Type p53 Gene",
G. Shaulsky et al, "Nuclear Localization is Essential for the Activity of
G. Shaulsky et al, "Nuclear Accumulation of p53 Protein is Mediated by Several Nuclear Localization Signals and Plays a Role in Tumorigenesis",
J. Oliner et al, "Amplification of a Gene Encoding a p53-Associated Protein
J. Oliner et al, "Oncoprotein MDM2 Conceals the Activation Domain of Tumour
J. Chen et al, "Heterogeneity of Transcriptional Activity of Mutant p53 Proteins and p53 DNA Target Sequences", Oncogene, 8:2159-2166 (Aug. 1993)
J. Chen et al, "Mapping of the p53 and mdm-2 Interaction Domains", Mol.
C. Harris, "p53: At the Crossroads of Molecular Carcinogenesis and Risk Assessment", Science, 262:1980-1981 (Dec. 24, 1993).
R. Zakut-Houri et al, "Human p53 Cellular Tumor Antigen: cDNA Sequence and Expression in COS Cells", EMBO J., 4(5):1251-1255 (May, 1985).
T. Soussi et al, "Structural Aspects of the p53 Protein in Relation to Gene Evolution", Oncogene, 5:945-952 (Jul., 1990).
J. Pietenpol et al, "Sequence-Specific Transcriptional Activation is Essential for Growth Suppression by p53", Proc. Natl. Acad. Sci. USA, 91:1998-2002 (Mar., 1994).
S. Kraiss et al, "Oligomerization of Oncoprotein p53", J. Virol., 62(12):4737-4744 (Dec., 1988).
T. Friedmann, "Gene Therapy of Cancer Through Restoration of Tumor-Suppressor Functions", Cancer Supplement, 70(6):1810-1817 (Sep. 15, 1992).
P. Friedman et al, "The p53 Protein is an Unusually Shaped Tetramer that Binds Directly to DNA", Proc. Natl. Acad. Sci. USA, 90:3319-3323 (Apr., 1993).
P. Hainaut et al, "Analysis of p53 Quaternary Structure in Relation to Sequence-Specific DNA Binding", Oncogene, 9:299-303 (Jan., 1994).
W. El-Deiry et al, "WAF1, a Potential Mediator of p53 Tumor Suppression", Cell, 75:817-825 (Nov. 19, 1993).
X. Wu et al, "The p53-mdm-2 Autoregulatory Feedback Loop", Genes & Development, 7:1126-1132 (Jul., 1993).
M. Kastan et al, "A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 is Defective in Ataxia-Telangiectasia", Cell, 71:587-597 (Nov. 13, 1992).
N. Pavletich et al, "The DNA-Binding Domain of p53 Contains the Four Conserved Regions and the Major Mutation Hot Spots", Genes & Development, 7:2556-2564 (Dec., 1993).
S. Fields et al, "Presence of a Potent Transcription Activating Sequence in the p53 Protein", Science, 249:1046-1049 (Aug. 31, 1990).
J. Bargonetti et al, "Site-Specific Binding of Wild-Type p53 to Cellular DNA is Inhibited by SV40 T Antigen and Mutant p53", Genes & Development, 6:1886-1898 (Oct., 1992).
C. Finlay et al, "The p53 Proto-Oncogene can Act as a Suppressor of Transformation", Cell, 57:1083-1093 (Jun. 30, 1989).
D. Eliyahu et al, "Wild-Type p53 can Inhibit Oncogene-Mediated Focus Formation", Proc. Natl. Acad. Sci. USA, 86:8763-8767 (Nov., 1989).
S. Baker et al, "Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53", Science, 249:912-915 (Aug. 24, 1990).
W. Mercer et al, "Negative Growth Regulation in a Glioblastoma Tumor Cell Line that Conditionally Expresses Human Wild-Type p53", Proc. Natl. Acad. Sci. USA, 87:6166-6170 (Aug., 1990).
W. Isaacs et al, "Wild-Type p53 Suppresses Growth of Human Prostate Cancer Cells Containing Mutant p53 Alleles", Cancer Res., 51:4716-4720 (Sep. 1, 1991).
S. Kern et al, "Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression", Science, 256:827-830 (May 8, 1992).
E. Yonish-Rouach et al, "p53-Mediated Cell Death: Relationship to Cell Cycle Control", Mol. Cell. Biol., 13(3):1415-1423 (Mar., 1993).
S. Lowe et al, "p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents", Cell, 74:957-967 (Sep. 24, 1993).
J. Milner et al, "Cotranslation of Activated Mutant p53 with Wild Type Drives the Wild-Type p53 Protein into the Mutant Conformation", Cell, 65:765-774 (May 31, 1991).
G. Farmer et al, "Wild-Type p53 Activates Transcription in vitro", Nature, 358:83-86 (Jul. 2, 1992).
H. Sakamoto et al, "Specific Sequences from the Carboxyl Terminus of Human p53 Gene Product Form Anti-Parallel Tetramers in Solution", Proc. Natl. Acad. Sci. USA, 91:8974-8978 (Sep., 1994).
J. Momand et al, "The mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation", Cell, 69:1237-1245 (Jun. 26, 1992).
J. Lin et al, "Several Hydrophobic Amino Acids in the p53 Amino-Terminal Domain are Required for Transcriptional Activation, Binding to mdm-2 and the Adenovirus 5 E1B 55-KD Protein", Genes & Development, 8:1235-1246 (May, 1994).
L. Cox et al, "Xenopus p53 is Biochemically Similar to the Human Tumour Suppressor Protein p53 and is Induced upon DNA Damage in Somatic Cells", Oncogene, 9:2951-2959 (Oct., 1994).
B. Li et al, "Preferential Overexpression of a 172Arg-Leu Mutant p53 in the Mammary Gland of Transgenic Mice Results in Altered Lobuloalveolar Development", Cell Growth and Differentiation, 5:711-721 (Jul., 1994).
J. Richardson et al, "Amino Acid Preferences for Specific Locations at the Ends of alpha Helices", Science, 240:1648-1652 (Jun. 17, 1988).
A. Chumakov et al, "Analysis of p53 Transactivation through High-Affinity Binding Sites", Oncogene, 8:3005-3011 (Nov., 1993).
C. Caron de Fromentel et al, "TP53 Tumor Suppressor Gene: A Model for Investigating Human Mutagenesis", Genes, Chrom. and Cancer, 4:1-15 (Jan., 1992).
E. Shaulian et al, "Tight DNA Binding and Oligomerization are Dispensable for the Ability of p53 to Transactivate Target Genes and Suppress Transformation", EMBO J., 12(7):2789-2797 (Jul., 1993).
S. Maheswaran et al, "Physical and Functional Interaction Between WT1 and p53 Proteins", Proc. Natl. Acad. Sci. USA, 90:5100-5104 (Jun., 1993).
T. Unger et al, "p53: a Transdominant Regulator of Transcription whose Function is Ablated by Mutations Occurring in Human Cancer", EMBO J.,
T. Unger et al, "Functional Domains of Wild-Type and Mutant p53 Proteins Involved in Transcriptional Regulation, Transdominant Inhibition, and Transformation Suppression", Mol. Cell. Biol., 13(9):5186-5194 (Sep.,
M. Reed et al, "p53 Domains: Suppression, Transformation, and Transactivation", Gene Expression, 3(1):95-107 (May, 1993).
C. Miller et al, "Mutant p53 Proteins Having Diverse Intracellular Abilities to Oligomerize and Activate Transcription", Oncogene, 8(7):1815-1824 (Jun., 1993).
K. Iwabuchi et al, "Use of the Two-Hybrid System to Identify the Domain of p53 Involved in Oligomerizatio
Pak Michael
The Wistar Institute of Anatomy and Biology
Walsh Stephen
LandOfFree
Modified p53 constructs which enhance DNA binding does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified p53 constructs which enhance DNA binding, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified p53 constructs which enhance DNA binding will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-178252